{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:03:54Z","timestamp":1761314634822,"version":"build-2065373602"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to analyze and compare the characteristics of patients with exudative age-related macular degeneration who were lost to follow-up after receiving intravitreal anti-vascular endothelial growth factor(anti-VEGF) injections versus those who maintained regular follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included patients who were lost to follow-up for more than 1 year (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200979) or maintained follow-up (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009186) after treatment with intravitreal injections of ranibizumab or aflibercept for exudative age-related macular degeneration. Age, sex, place of residence, type of health insurance, distance from the hospital, laterality of involvement, and follow-up duration were analyzed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were no significant differences between the two groups in terms of age, sex, or type of health insurance. However, patients lost to follow-up resided significantly further from the hospital versus those with regular follow-up (33.1\u2009\u00b1\u200926.8 vs. 21.6\u2009\u00b1\u20098.5\u00a0km;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001). A significantly higher proportion of patients that were lost to follow-up had unilateral involvement (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and resided in rural areas (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Distance from the hospital, rural residency, and unilateral involvement are significantly associated with nonadherence to follow-up among patients with exudative age-related macular degeneration receiving intravitreal anti-VEGF injections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-025-04426-9","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:00:28Z","timestamp":1761314428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics of patients lost to follow-up after intravitreal anti-vascular endothelial growth factor therapy for exudative age-related macular degeneration"],"prefix":"10.1186","volume":"25","author":[{"given":"Yongwun","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woong-Sun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong-Jae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inyoung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"11","key":"4426_CR1","first-page":"844","volume":"82","author":"S Resnikoff","year":"2004","unstructured":"Resnikoff S, Pascolini D, Etya\u2019ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844\u20135.","journal-title":"Bull World Health Organ"},{"issue":"14","key":"4426_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"4426_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57\u201365.","journal-title":"Ophthalmology"},{"issue":"12","key":"4426_CR4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology"},{"issue":"1","key":"4426_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3341\/jkos.2019.60.1.40","volume":"60","author":"IH Lee","year":"2019","unstructured":"Lee IH, Lee JJ, Kwon HJ, Park SW, Lee JE. Clinical changes after switching from ranibizumab\/aflibercept to bevacizumab in exudative age-related macular degeneration. J Korean Ophthalmol Soc. 2019;60(1):40.","journal-title":"J Korean Ophthalmol Soc"},{"issue":"1","key":"4426_CR6","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1186\/s12913-019-4666-0","volume":"19","author":"S Kim","year":"2019","unstructured":"Kim S, Park SJ, Byun SJ, Park KH, Suh HS. Incremental economic burden associated with exudative age-related macular degeneration: a population-based study. BMC Health Serv Res. 2019;19(1):828.","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"4426_CR7","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3341\/jkos.2021.62.7.948","volume":"62","author":"WT Yoon","year":"2021","unstructured":"Yoon WT, Kim JW, Kim CG, Kim JH. Proportion and reasons for ineligibility to re-register for extended health insurance in neovascular age-related macular degeneration. J Korean Ophthalmol Soc. 2021;62(7):948\u201356.","journal-title":"J Korean Ophthalmol Soc"},{"issue":"11","key":"4426_CR8","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jamaophthalmol.2018.3578","volume":"136","author":"A Obeid","year":"2018","unstructured":"Obeid A, Gao X, Ali FS, Aderman CM, Shahlaee A, Adam MK, et al. Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti-vascular endothelial growth factor injections. JAMA Ophthalmol. 2018;136(11):1251.","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"4426_CR9","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1097\/IAE.0000000000001494","volume":"37","author":"JH Kim","year":"2017","unstructured":"Kim JH, Chang YS, Kim JW. Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis. Retina. 2017;37(12):2254\u201361.","journal-title":"Retina"},{"issue":"1","key":"4426_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajo.2012.06.031","volume":"155","author":"M Kr\u00fcger Falk","year":"2013","unstructured":"Kr\u00fcger Falk M, Kemp H, S\u00f8rensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol. 2013;155(1):89\u201395.","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"4426_CR11","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1097\/IAE.0000000000000173","volume":"34","author":"A Vaze","year":"2014","unstructured":"Vaze A, Fraser-Bell S, Gillies M. Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration. Retina. 2014;34(9):1774\u20138.","journal-title":"Retina"},{"issue":"4","key":"4426_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4274\/tjo.28003","volume":"47","author":"O Polat","year":"2017","unstructured":"Polat O, \u0130nan S, \u00d6zcan S, Do\u011fan M, K\u00fcsbeci T, Yava\u015f GF, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration. Turk Oftalmoloji Derg. 2017;47(4):205\u201310.","journal-title":"Turk Oftalmoloji Derg"},{"issue":"2","key":"4426_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","volume":"4","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Skelly A, Bezlyak V, Griner R, Torres LR, Sagkriotis A. Sierra-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2020;4(2):122\u201333.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"4426_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/eye.2012.225","volume":"27","author":"AH Ross","year":"2013","unstructured":"Ross AH, Donachie PHJ, Sallam A, Stratton IM, Mohamed Q, Scanlon PH, et al. Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab? Eye. 2013;27(1):56\u201364.","journal-title":"Eye"},{"issue":"4","key":"4426_CR15","first-page":"88","volume":"130","author":"EV Bobykin","year":"2014","unstructured":"Bobykin EV. The influence of patient compliance with antiangiogenic therapy on its efficacy for neovascular age-related macular degeneration. Vestn Oftalmol. 2014;130(4):88\u201396.","journal-title":"Vestn Oftalmol"},{"issue":"6","key":"4426_CR16","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1097\/IAE.0000000000001681","volume":"38","author":"C Ehlken","year":"2018","unstructured":"Ehlken C, Wilke T, Bauer-Steinhusen U, Agostini H, Hasanbasic Z, Treatment OF Neovascular age-related macular degeneration patients with vascular endothelial growth factor inhibitors in everyday practice, et al. Identification of health care constraints in Germany- the PONS study. Retina. 2018;38(6):1134\u201344.","journal-title":"Retina"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04426-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04426-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04426-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:00:29Z","timestamp":1761314429000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04426-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4426"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04426-9","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective observational study was approved by the Institutional Review Board (IRB) of Gyeongsang National University Jinju Hospital (IRB No. 2023-11-019). The need for informed consent was waived because of deidentified data handling and the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"598"}}